Development Status and Quality Evaluation on Clinical Practice Guidelines for the Treatment of Dominant Diseases with Chinese Patent Medicines
Objective To analyze the development status and quality of clinical practice guidelines for the treat-ment of dominant diseases with Chinese patent medicines(CPMs).Methods Databases were searched from Jan.2019 to Dec.2023 to collect the published clinical practice guidelines of CPMs for the treatment of dominant diseases.The information about the title,the participants,clinical problems,outcomes,evidence grade,recommendations,and recommendation strength in the included clinical practice guidelines were collected,for which the development status was analyzed,and the quality was evaluated with the Scientific,Transparent and Applicable Rankings(STAR)tool for clinical practice guidelines.Results Totally,34 guidelines were included,involving 273 kinds of CPMs.One to ten(with the medium five)clinical problems were proposed from 29 clinical practice guidelines respectively.All the guidelines divided the evidence into four grades according to Grade of Recommendation Assessment,Deve-lopement an Evaluation.And 28 guidelines had five levels of recommendation strength.A total of 344 recommenda-tions were extracted,including 86 strong-recommendations,191 weak-recommendations(including 36 weak recommen-dations only based on expert consensus)and 67 recommendations with unclear recommendation strength.All guide-lines had high scores in the three areas of"clinical questions(94.20％)","evidence(91.45％)"and"recommenda-tions(89.06％)",while the scores in the three areas of"registry(22.06％)","protocol(19.00％)"and"accessibility(31.51％)"were low.The STAR recommended stars of 8 guidelines were 5.0～4.0 stars,while that of 18 guidelines were 3.5～2.5 stars,and 8 guidelines were 2.0～1.0 stars.The three guidelines with the highest recommended stars were depressive disorder,community-acquired pneumonia,and influenza in adult.Conclusion There is a certain gap in the quality of the published clinical practice guidelines of CPMs,and the quality of the guidelines could be fur-ther improved in registry,protocols,funds,and accessibility.
Chinese patent medicinedominant diseasesclinical practice guidelinesquality evaluationSTAR
NETL
NSTL
万方数据
